Company / Working Capital
SAB Biotherapeutics, Inc. Working Capital History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$90.4M
FY2025
5-year range
$15.8M / $90.4M
FY2021-FY2025
Trend
+471.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital changed +472% YoY in FY2025, a notable deviation from the 4-year average annual change of +127%.
Based on SEC 10-K filings.
$90M in FY2025 with a 3-year CAGR of +56.1%.
Improved from $48M to $90M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- +56.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +56.1%, indicating consistent growth.
- In FY2025, working capital increased 471.5% year-over-year.
- Lowest working capital in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $90.4M | +471.5% |
| FY2024 | $15.8M | -67.1% |
| FY2023 | $48.1M | +102.6% |
| FY2022 | $23.7M | +1.5% |
| FY2021 | $23.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026